

Anirban Basu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9210790/publications.pdf>

Version: 2024-02-01

141
papers

7,295
citations

136950

32
h-index

60623

81
g-index

147
all docs

147
docs citations

147
times ranked

9390
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2016, 316, 1093.	7.4	2,149
2	Two-stage residual inclusion estimation: Addressing endogeneity in health econometric modeling. Journal of Health Economics, 2008, 27, 531-543.	2.7	1,212
3	Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]. Value in Health, 2018, 21, 131-139.	0.3	321
4	Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics, 2005, 6, 93-109.	1.5	302
5	Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Economics (United Kingdom), 2007, 16, 1133-1157.	1.7	149
6	Implications of spillover effects within the family for medical cost-effectiveness analysis. Journal of Health Economics, 2005, 24, 751-773.	2.7	137
7	HIGHLIGHTING DIFFERENCES BETWEEN CONDITIONAL AND UNCONDITIONAL QUANTILE REGRESSION APPROACHES THROUGH AN APPLICATION TO ASSESS MEDICATION ADHERENCE. Health Economics (United Kingdom), 2011, 30, 1114-1134.	0.7	83
8	Risk Stratification for Sudden Cardiac Death. Circulation, 2014, 129, 516-526.	1.6	131
9	Regression Estimators for Generic Health-Related Quality of Life and Quality-Adjusted Life Years. Medical Decision Making, 2012, 32, 56-69.	2.4	122
10	Value of Information on Preference Heterogeneity and Individualized Care. Medical Decision Making, 2007, 27, 112-127.	2.4	117
11	A Health Economics Approach to US Value Assessment Frameworks—Summary and Recommendations of the ISPOR Special Task Force Report [7]. Value in Health, 2018, 21, 161-165.	0.3	113
12	Issues for the Next Generation of Health Care Cost Analyses. Medical Care, 2009, 47, S109-S114.	2.4	110
13	Value of Information Analysis for Research Decisions—An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 139-150.	0.3	105
14	Comparative Cost Analysis of Housing and Case Management Program for Chronically Ill Homeless Adults Compared to Usual Care. Health Services Research, 2012, 47, 523-543.	2.0	98
15	Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. Health Affairs, 2020, 39, 1229-1236.	5.2	97
16	In-Hospital Outcomes and Costs Among Patients Hospitalized During a Return Visit to the Emergency Department. JAMA - Journal of the American Medical Association, 2016, 315, 663.	7.4	90
17	Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force. Value in Health, 2020, 23, 277-286.	0.3	75
18	Overview of Cost-effectiveness Analysis. JAMA - Journal of the American Medical Association, 2019, 321, 1400.	7.4	71

#	ARTICLE	IF	CITATIONS
19	Estimating lifetime or episode of illness costs under censoring. Health Economics (United Kingdom), 2010, 19, 1010-1028.	1.7	64
20	Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. Health Economics (United Kingdom), 2006, 15, 1091-1107.	1.7	61
21	Economics of individualization in comparative effectiveness research and a basis for a patient-centered health care. Journal of Health Economics, 2011, 30, 549-559.	2.7	60
22	Approaches to Aggregation and Decision Making – A Health Economics Approach: An ISPOR Special Task Force Report [5]. Value in Health, 2018, 21, 146-154.	0.3	59
23	Future Directions for Cost-effectiveness Analyses in Health and Medicine. Medical Decision Making, 2018, 38, 767-777.	2.4	58
24	Minimal Modeling Approaches to Value of Information Analysis for Health Research. Medical Decision Making, 2011, 31, E1-E22.	2.4	53
25	Workplace Stress and Working from Home Influence Depressive Symptoms Among Employed Women with Young Children. International Journal of Behavioral Medicine, 2016, 23, 102-111.	1.7	51
26	<sc>2SLS</sc> versus <sc>2SRI</sc>: <sc>A</sc>ppropriate methods for rare outcomes and/or rare exposures. Health Economics (United Kingdom), 2018, 27, 937-955.	1.7	42
27	A Time Tradeoff Method for Eliciting Partner's Quality of Life due to Patient's Health States in Prostate Cancer. Medical Decision Making, 2010, 30, 355-365.	2.4	38
28	ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS. Journal of Applied Econometrics, 2014, 29, 671-691.	2.3	38
29	The impact of comparative effectiveness research on health and health care spending. Journal of Health Economics, 2011, 30, 695-706.	2.7	36
30	Impact of Medicare Part D on Medicare "Medicaid Dual" Eligible Beneficiaries' Prescription Utilization and Expenditures. Health Services Research, 2010, 45, 133-151.	2.0	35
31	Individualization at the Heart of Comparative Effectiveness Research: The Time for i-CER Has Come. Medical Decision Making, 2009, 29, NP9-NP11.	2.4	33
32	Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures. Medical Care, 2017, 55, 191-198.	2.4	33
33	Medicare expenditures attributable to dementia. Health Services Research, 2019, 54, 773-781.	2.0	33
34	Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. JAMA - Journal of the American Medical Association, 2019, 321, 1096.	7.4	33
35	Regression Discontinuity Design. JAMA - Journal of the American Medical Association, 2020, 324, 381.	7.4	33
36	Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Research, 2006, 86, 99-109.	2.0	32

#	ARTICLE	IF	CITATIONS
37	Social costs of robbery and the cost-effectiveness of substance abuse treatment. Health Economics (United Kingdom), 2008, 17, 927-946.	1.7	32
38	Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Services Research, 2019, 54, 1055-1064.	2.0	28
39	Estimating treatment effects on healthcare costs under exogeneity: is there a "magic bullet"? Health Services and Outcomes Research Methodology, 2011, 11, 1-26.	1.8	26
40	Effects of Maternity Care Coordination on Pregnancy Outcomes: Propensity-Weighted Analyses. Maternal and Child Health Journal, 2015, 19, 121-127.	1.5	26
41	Forecasting Distribution of Body Mass Index in the United States: Is There More Room for Growth?. Medical Decision Making, 2010, 30, E1-E11.	2.4	25
42	The Economics of Comparative Effectiveness Studies. Pharmacoeconomics, 2010, 28, 843-853.	3.3	25
43	Transitional care clinics for follow-up and primary care linkage for patients discharged from the ED. American Journal of Emergency Medicine, 2016, 34, 1230-1235.	1.6	25
44	Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making, 2016, 36, 641-651.	2.4	25
45	Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health, 2020, 23, 96-103.	0.3	25
46	Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis. , 2016, , 201-236.		23
47	Minimum Threshold of Bariatric Surgical Weight Loss for Initial Diabetes Remission. Diabetes Care, 2022, 45, 92-99.	8.6	23
48	A linear index for predicting joint health states utilities from single health states utilities. Health Economics (United Kingdom), 2009, 18, 403-419.	1.7	22
49	HETEROGENEITY IN ACTION: THE ROLE OF <i>PASSIVE</i> PERSONALIZATION IN COMPARATIVE EFFECTIVENESS RESEARCH. Health Economics (United Kingdom), 2014, 23, 359-373.	1.7	22
50	Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. Pharmacoeconomics, 2020, 38, 57-68.	3.3	22
51	Financing cures in the United States. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 1-4.	1.4	21
52	Does Maternity Care Coordination Influence Perinatal Health Care Utilization? Evidence from North Carolina. Health Services Research, 2018, 53, 2368-2383.	2.0	20
53	Analysis of Benefit of Intensive Care Unit Transfer for Deteriorating Ward Patients. JAMA Network Open, 2019, 2, e187704.	5.9	20
54	Estimating Decision-Relevant Comparative Effects Using Instrumental Variables. Statistics in Biosciences, 2011, 3, 6-27.	1.2	19

#	ARTICLE	IF	CITATIONS
55	Comparative Effectiveness Research For Antipsychotic Medications: How Much Is Enough?. Health Affairs, 2009, 28, w794-w808.	5.2	16
56	Are Elderly Patients With Clinically Localized Prostate Cancer Overtreated? Exploring Heterogeneity in Survival Effects. Medical Care, 2015, 53, 79-86.	2.4	16
57	The effect of prenatal exposure to Ramadan on children's height. Economics and Human Biology, 2018, 30, 69-83.	1.7	16
58	Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Economics (United Kingdom), 2019, 28, 855-867.	1.7	15
59	Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study. Hypertension, 2021, 78, 1116-1125.	2.7	15
60	Longitudinal trends and predictors of statin use among patients with diabetes. Journal of Diabetes and Its Complications, 2018, 32, 27-33.	2.3	14
61	Heterogeneity in the impact of type of schooling on adult health and lifestyle. Journal of Health Economics, 2018, 57, 1-14.	2.7	14
62	How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health, 2019, 22, 777-784.	0.3	14
63	Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis. PharmacoEconomics - Open, 2022, 6, 469-481.	1.8	14
64	CAN WE MAKE SMART CHOICES BETWEEN OLS AND CONTAMINATED IV METHODS?. Health Economics (United Kingdom), 2014, 23, 462-472.	1.7	13
65	Parental Predictions and Perceptions Regarding Long-Term Childhood Obesity-Related Health Risks. Academic Pediatrics, 2016, 16, 475-481.	2.0	13
66	Alternative evaluation metrics for risk adjustment methods. Health Economics (United Kingdom), 2018, 27, 984-1010.	1.7	13
67	Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social and Administrative Pharmacy, 2020, 16, 1033-1040.	3.0	13
68	Quality-Adjusted Life-Year Losses Averted With Every COVID-19 Infection Prevented in the United States. Value in Health, 2021, 24, 632-640.	0.3	13
69	A Framework for Prioritizing Research Investments in Precision Medicine. Medical Decision Making, 2016, 36, 567-580.	2.4	12
70	Price elasticities of pharmaceuticals in a value based formulary setting. Health Economics (United Kingdom), 2019, 28, 1033-1040.	2.7	12
71	The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry, 2022, 22, 32.	2.6	11
72	Financing a Cure for Diabetes in a Multipayer Environment. Value in Health, 2016, 19, 861-868.	0.3	10

#	ARTICLE	IF	CITATIONS
73	Measuring the Value of Pharmaceuticals in the US Health System. <i>Pharmacoeconomics</i> , 2017, 35, 1-4.	3.3	10
74	Decision Criterion and Value of Information Analysis: Optimal Aspirin Dosage for Secondary Prevention of Cardiovascular Events. <i>Medical Decision Making</i> , 2018, 38, 427-438.	2.4	10
75	Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 529-537.	0.9	10
76	A welfare-theoretic model consistent with the practice of cost-effectiveness analysis and its implications. <i>Journal of Health Economics</i> , 2020, 70, 102287.	2.7	10
77	Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 759-768.	0.9	9
78	Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis. <i>Value in Health</i> , 2021, 24, 957-965.	0.3	9
79	Toward a Hedonic Value Framework in Health Care. <i>Value in Health</i> , 2017, 20, 261-265.	0.3	8
80	New Metrics for Economic Evaluation in the Presence of Heterogeneity: Focusing on Evaluating Policy Alternatives Rather than Treatment Alternatives. <i>Medical Decision Making</i> , 2017, 37, 930-941.	2.4	8
81	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 1321-1328.	2.1	8
82	Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. <i>Cancer Medicine</i> , 2018, 7, 4251-4260.	2.8	8
83	Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. <i>Pharmacoeconomics</i> , 2019, 37, 1321-1327.	3.3	8
84	Health Economics Tools and Precision Medicine: Opportunities and Challenges. <i>Forum for Health Economics and Policy</i> , 2020, 23, .	0.8	8
85	Association of Branded Prescription Drug Rebate Size and Patient Out-of-Pocket Costs in a Nationally Representative Sample, 2007-2018. <i>JAMA Network Open</i> , 2021, 4, e2113393.	5.9	8
86	Effectiveness of Gastric Bypass Versus Gastric Sleeve for Cardiovascular Disease: Protocol and Baseline Results for a Comparative Effectiveness Study. <i>JMIR Research Protocols</i> , 2020, 9, e14936.	1.0	8
87	Welfare implications of learning through solicitation versus diversification in health care. <i>Journal of Health Economics</i> , 2015, 42, 165-173.	2.7	7
88	Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 1084-1090.	0.9	7
89	Bezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy218.	0.9	7
90	The Value of Outpatient Imaging-Based Cancer Screening Episodes. <i>Journal of General Internal Medicine</i> , 2018, 33, 1571-1573.	2.6	7

#	ARTICLE	IF	CITATIONS
91	The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature. <i>Pharmacoeconomics</i> , 2021, 39, 1225-1241.	3.3	7
92	Person-centered Treatment (PeT) Effects: Individualized Treatment Effects Using Instrumental Variables. <i>The Stata Journal</i> , 2015, 15, 397-410.	2.2	6
93	Real-World Data. <i>Medical Care</i> , 2016, 54, 1038-1044.	2.4	5
94	Washington's privatization of liquor: effects on household alcohol purchases from Initiative 1183. <i>Addiction</i> , 2020, 115, 681-689.	3.3	5
95	Difficulty with Taking Medications Is Associated with Future Diagnosis of Alzheimer's Disease and Related Dementias. <i>Journal of General Internal Medicine</i> , 2021, 36, 863-868.	2.6	5
96	Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach. <i>Statistics in Medicine</i> , 2006, 25, 2886-2910.	1.6	4
97	Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. <i>Medical Decision Making</i> , 2019, 39, 137-151.	2.4	4
98	Impact of a value-based formulary in three chronic disease cohorts. <i>American Journal of Managed Care</i> , 2017, 23, S46-S53.	1.1	4
99	Impact of a statewide Emergency Department Information Exchange on health care use and expenditures. <i>Health Services Research</i> , 2022, 57, 603-613.	2.0	4
100	Comparative effectiveness of gastric bypass and sleeve gastrectomy on predicted 10-year risk of cardiovascular disease 5 years after surgery. <i>Surgery for Obesity and Related Diseases</i> , 2022, , .	1.2	4
101	Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. <i>PLoS ONE</i> , 2022, 17, e0267448.	2.5	4
102	Tying comparative effectiveness information to decision-making and the future of comparative effectiveness research designs: the case for antipsychotic drugs. <i>Journal of Comparative Effectiveness Research</i> , 2012, 1, 171-180.	1.4	3
103	Private Manufacturers' Thresholds to Invest in Comparative Effectiveness Trials. <i>Pharmacoeconomics</i> , 2012, 30, 859-868.	3.3	3
104	Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review. <i>Value in Health</i> , 2022, 25, 276-287.	0.3	3
105	Patient-centered or "central" patient: Raising the veil of ignorance over randomization. <i>Statistics in Medicine</i> , 2012, 31, 3057-3059.	1.6	2
106	Personalized Medicine in the Context of Comparative Effectiveness Research. <i>Forum for Health Economics and Policy</i> , 2013, 16, S73-S86.	0.8	2
107	Returns to scientific publications for pharmaceutical products in the United States. <i>Health Economics (United Kingdom)</i> , 2018, 27, 282-293.	1.7	2
108	Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013. <i>Pharmacoeconomics</i> , 2019, 37, 1287-1300.	3.3	2

#	ARTICLE	IF	CITATIONS
109	Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. <i>Value in Health</i> , 2019, 22, 988-994.	0.3	2
110	Health Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion. <i>American Journal of Health Economics</i> , 2019, 5, 360-375.	3.0	2
111	How can clinical researchers quantify the value of their proposed comparative research?. <i>American Heart Journal</i> , 2019, 209, 116-125.	2.7	2
112	Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. <i>Personalized Medicine</i> , 2020, 17, 389-398.	1.5	2
113	Evidence generation, decision making, and consequent growth in health disparities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14042-14051.	7.1	2
114	Improving risk adjustment with machine learning: accounting for service-level propensity scores to reduce service-level selection. <i>Health Services and Outcomes Research Methodology</i> , 2021, 21, 363-388.	1.8	2
115	Estimating Endogenous Treatment Effects Using Latent Factor Models with and without Instrumental Variables. <i>Econometrics</i> , 2021, 9, 14.	0.9	2
116	Quantitative Methods for Valuing Comparative Effectiveness Information. , 2010, 17, 2-10.		2
117	A sub-group evaluation of the multi-month dispensing strategy for differentiated HIV care: is personalization of care guidelines warranted in Haiti?. <i>BMC Health Services Research</i> , 2022, 22, 80.	2.2	2
118	Public spending on acute and long-term care for Alzheimer's disease and related dementias. <i>Alzheimer's and Dementia</i> , 2023, 19, 150-157.	0.8	2
119	Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease. <i>Quality of Life Research</i> , 2022, 31, 2729-2738.	3.1	2
120	Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 163-165.	1.4	1
121	Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers. <i>Journal of Comparative Effectiveness Research</i> , 2017, 6, 15-24.	1.4	1
122	Postdischarge Unplanned Care Events Among Commercially Insured Patients With an Observation Stay Versus Short Inpatient Admission. <i>Annals of Emergency Medicine</i> , 2019, 74, 334-344.	0.6	1
123	Assessing Health Care Burden in Glaucoma Patients with and Without Physical or Mental Comorbidities. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020, 26, 325-331.	0.9	1
124	Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 193-204.	2.2	1
125	Real-world patterns on tumor mutation burden testing in a pan-tumor population. <i>Future Oncology</i> , 2021, 17, 1879-1887.	2.4	1
126	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. <i>BMJ Open</i> , 2021, 11, e046912.	1.9	1

#	ARTICLE	IF	CITATIONS
127	Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 95-104.	0.9	1
128	RESPONSE TO EPSTEIN'S COMMENT ON "HETEROGENEITY IN ACTION". <i>Health Economics (United Kingdom)</i> , 2018, 27, 1422-1424.	1.7	0
129	Real-World Data: Responses to Zito and Doshi. <i>Medical Care</i> , 2016, 54, 1048-1049.	2.4	0
130	Individualization of Treatment and Comparative Effectiveness Research. , 2016, , 255-274.		0
131	Comment: Manski's views on patient care under uncertainty. <i>Health Economics (United Kingdom)</i> , 2018, 27, 1422-1424.	1.7	0
132	Time Horizons in Cost Analyses—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 582.	7.4	0
133	Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. <i>Pharmacoeconomics</i> , 2020, 38, 171-179.	3.3	0
134	Meta-analyzing count events over varying durations using the piecewise Poisson model: The case for poststroke seizures. <i>Research Synthesis Methods</i> , 2021, 12, 347-356.	8.7	0
135	Do pharmaceutical prices rise anticipating branded competition?. <i>Health Economics (United Kingdom)</i> , 2021, 30, 1070-1081.	1.7	0
136	Trends in health-related quality of life (HRQoL) and income over time in older adults with and without cancer: Evidence from the Surveillance, Epidemiology, and End Results—Medicare Health Outcomes Survey (SEER—MHOS) linked database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9603-9603.	1.6	0
137	Individualization of Treatment and Comparative Effectiveness Research. , 2015, , 1-21.		0
138	Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6506-6506.	1.6	0
139	Predicting low accrual in the Clinical Trials Cooperative Group Program's phase II/III oncology trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6522-6522.	1.6	0
140	Impact of value of research analyses on SWOG's clinical trial capsule scoring.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18311-e18311.	1.6	0
141	A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing. <i>Medical Decision Making</i> , 2021, , 0272989X2110492.	2.4	0